Understanding and Overcoming Tumor Heterogeneity in Metastatic Breast Cancer Treatment

Overview

Journal Nat Cancer

Specialty Oncology

Date 2022 Feb 5

PMID 35121946

Authors

Nida Pasha

Nicholas C Turner

Affiliations

Soon will be listed here.

Abstract

Rational development of targeted therapies has revolutionized metastatic breast cancer outcomes, although resistance to treatment remains a major challenge. Advances in molecular profiling and imaging technologies have provided evidence for the impact of clonal diversity in cancer treatment resistance, through the outgrowth of resistant clones. In this Review, we focus on the genomic processes that drive tumoral heterogeneity and the mechanisms of resistance underlying metastatic breast cancer treatment and discuss implications for future treatment strategies.

Citing Articles

MRPL24 drives breast cancer metastasis and stemness by targeting c-MYC, BRD4, and STAT3.

Khan A, Khan I, Man S, Liu S, Ailun G, Abbas M 3 Biotech. 2025; 15(2):37.

PMID: 39802327 PMC: 11718041. DOI: 10.1007/s13205-024-04196-z.

Personalized multifactorial risk assessment in neoadjuvant-treated breast carcinoma.

Korpinen K, Autere T, Tuominen J, Loyttyniemi E, Eigeliene N, Talvinen K Breast Cancer Res Treat. 2024; .

PMID: 39739270 DOI: 10.1007/s10549-024-07584-4.

Targeted NIR-triggered doxorubicin release using carbon dots-poly(ethylene glycol)-folate conjugates for breast cancer treatment.

Varvara P, Mauro N, Cavallaro G Nanoscale Adv. 2024; 7(3):862-875.

PMID: 39711616 PMC: 11660423. DOI: 10.1039/d4na00834k.

Modeling intratumor heterogeneity in breast cancer.

McDonough E, Barroso M, Ginty F, Corr D Biofabrication. 2024; 17(1.

PMID: 39642392 PMC: 11740194. DOI: 10.1088/1758-5090/ad9b50.

RNA methylation and breast cancer: insights into m6A, m7G and m5C.

Dai Y, Zhao S, Chen H, Yu W, Fu Z, Cui Y Mol Biol Rep. 2024; 52(1):27.

PMID: 39611867 DOI: 10.1007/s11033-024-10138-y.

References

Caswell-Jin J, Plevritis S, Tian L, Cadham C, Xu C, Stout N . Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review. JNCI Cancer Spectr. 2019; 2(4):pky062. PMC: 6305243. DOI: 10.1093/jncics/pky062. View

Swain S, Miles D, Kim S, Im Y, Im S, Semiglazov V . Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020; 21(4):519-530. DOI: 10.1016/S1470-2045(19)30863-0. View

Im S, Lu Y, Bardia A, Harbeck N, Colleoni M, Franke F . Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019; 381(4):307-316. DOI: 10.1056/NEJMoa1903765. View

OLeary B, Cutts R, Liu Y, Hrebien S, Huang X, Fenwick K . The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. Cancer Discov. 2018; 8(11):1390-1403. PMC: 6368247. DOI: 10.1158/2159-8290.CD-18-0264. View

Gerlinger M, Rowan A, Horswell S, Math M, Larkin J, Endesfelder D . Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10):883-892. PMC: 4878653. DOI: 10.1056/NEJMoa1113205. View

Greaves M, Maley C . Clonal evolution in cancer. Nature. 2012; 481(7381):306-13. PMC: 3367003. DOI: 10.1038/nature10762. View

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

Lehmann B, Bauer J, Chen X, Sanders M, Chakravarthy A, Shyr Y . Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750-67. PMC: 3127435. DOI: 10.1172/JCI45014. View

Wang Y, Waters J, Leung M, Unruh A, Roh W, Shi X . Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 2014; 512(7513):155-60. PMC: 4158312. DOI: 10.1038/nature13600. View

10.

Hu Z, Li Z, Ma Z, Curtis C . Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. Nat Genet. 2020; 52(7):701-708. PMC: 7343625. DOI: 10.1038/s41588-020-0628-z. View

11.

Nik-Zainal S, Alexandrov L, Wedge D, Van Loo P, Greenman C, Raine K . Mutational processes molding the genomes of 21 breast cancers. Cell. 2012; 149(5):979-93. PMC: 3414841. DOI: 10.1016/j.cell.2012.04.024. View

12.

Priestley P, Baber J, Lolkema M, Steeghs N, de Bruijn E, Shale C . Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019; 575(7781):210-216. PMC: 6872491. DOI: 10.1038/s41586-019-1689-y. View

13.

Pride N . The assessment of airflow obstruction. Role of measurements of airways resistance and of tests of forced expiration. Br J Dis Chest. 1971; 65:135-69. DOI: 10.1016/0007-0971(71)90018-0. View

14.

Long R, Knutsen G, Robinson M . Myeloid hyperplasia in the SENCAR mouse: differentiation from granulocytic leukemia. Environ Health Perspect. 1986; 68:117-23. PMC: 1474249. DOI: 10.1289/ehp.8668117. View

15.

Bertucci F, Ng C, Patsouris A, Droin N, Piscuoglio S, Carbuccia N . Genomic characterization of metastatic breast cancers. Nature. 2019; 569(7757):560-564. DOI: 10.1038/s41586-019-1056-z. View

16.

Brown D, Smeets D, Szekely B, Larsimont D, Szasz A, Adnet P . Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. Nat Commun. 2017; 8:14944. PMC: 5474888. DOI: 10.1038/ncomms14944. View

17.

Yates L, Knappskog S, Wedge D, Farmery J, Gonzalez S, Martincorena I . Genomic Evolution of Breast Cancer Metastasis and Relapse. Cancer Cell. 2017; 32(2):169-184.e7. PMC: 5559645. DOI: 10.1016/j.ccell.2017.07.005. View

18.

De Mattos-Arruda L, Sammut S, Ross E, Bashford-Rogers R, Greenstein E, Markus H . The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer. Cell Rep. 2019; 27(9):2690-2708.e10. PMC: 6546974. DOI: 10.1016/j.celrep.2019.04.098. View

19.

Nowell P . The clonal evolution of tumor cell populations. Science. 1976; 194(4260):23-8. DOI: 10.1126/science.959840. View

20.

Alexandrov L, Nik-Zainal S, Wedge D, Aparicio S, Behjati S, Biankin A . Signatures of mutational processes in human cancer. Nature. 2013; 500(7463):415-21. PMC: 3776390. DOI: 10.1038/nature12477. View